A strong bearish view is presented on the Quantum Computing sector, suggesting investors avoid or consider shorting stocks like IONQ and QBTS due to skepticism about their business models. High-conviction short ideas include ProKidney (PROK), based on fundamental doubts about its core science, and Anavex (AVXL), on the belief its drug is ineffective. Ultragenyx (RARE) faces a near-term bearish outlook after a negative clinical trial update, increasing its risk profile significantly. Conversely, confidence remains high in Nvidia (NVDA), as the immense and ongoing demand for its AI chips supports continued growth. For highly risk-tolerant investors, Kala Bio (KALA) is presented as a speculative "lotto ticket" with the potential for a 10x return if its upcoming trial data is positive.

ProKidney (PROK)

• The speaker expresses extreme skepticism and a bearish outlook on ProKidney, stating, "I don't trust this thing at all."
• The core of the skepticism lies in the company's science. They are developing a cell therapy for kidney disease but allegedly "won't explain how they take the cell, what they do to it, and they just inject it back into the kidney." The speaker believes, "that is not how medicine works."
• He considered shorting the stock, noting a very high borrow fee of 126%, which indicates a significant number of other investors are also betting against the company.
• He later regrets not shorting it at $7, which he identified as the "exact fucking top."

Takeaways

• This is presented as a high-conviction short idea based on fundamental doubts about the company's scientific approach and lack of transparency.
• Investors should be aware that the high borrow fee makes this an expensive and potentially crowded short trade, meaning risk is elevated.
• The skepticism is part of a broader bearish view on cell therapies that don't involve genetically modifying the cells (see Cell Therapy theme below).

Kala Bio (KALA)

• The speaker analyzes Kala Bio, a "tiny market cap" company that he typically wouldn't look at.
• The company's future hinges on a treatment for persistent corneal epithelial defects using mesenchymal stem cells.
• The speaker is generally very doubtful about this type of cell therapy, stating, "Typically, these stem cells are terrible. They never work."
• However, he notes a key difference: the therapy is applied to the eye, which is an "immune privileged area," meaning the normal rules might not apply. He says, "never say never."
• The stock is described as a high-risk, high-reward play. It is "so beat up and dead that any possible success would be an instant 10x." It's an "afterthought company... on its ass and one good data set brings it back to life."

Takeaways

• KALA is positioned as a highly speculative, "lotto ticket" type of investment suitable only for investors with a very high risk tolerance.
• The investment thesis is binary: if their lead drug trial fails (which is considered likely based on the history of similar therapies), the stock is likely worthless. If it succeeds, the returns could be enormous.
• The key factor to watch is the data from their Chase trial.

Nvidia (NVDA)

• The speaker notes Nvidia's continued success, congratulating it on reaching a four trillion dollar market cap.
• He highlights the immense and ongoing demand for Nvidia's products, which are crucial for the AI buildout.
• He gives a specific example of the capital required: "You need money to, you know, buy 2,400 Blackwells for $130 million. And they're raising money to buy even more GPUs, I mean... The demand is there."

Takeaways

• The commentary is strongly bullish, reinforcing the narrative that demand for Nvidia's AI chips remains incredibly strong.
• This suggests continued confidence in Nvidia's central role in the AI industry and its potential for further growth.

Ultragenyx Pharmaceutical (RARE)

• The speaker was actively looking into RARE during the stream.
• While he was analyzing it, the company released an update on its study for osteogenesis imperfecta.
• The key news was that they did not stop the study early for an interim analysis, which was perceived as a negative development. He says, "they did not study the study early. They thought they would. Uh-oh."
• He notes that "Rare is pretty dependent on this fucking thing," implying the company's value is heavily tied to the success of this one drug.

Takeaways

• The news during the stream is a bearish short-term catalyst for RARE. The market often interprets the lack of an early stop for success as a sign the data is not overwhelmingly positive.
• This increases the risk profile for the stock, as its future is highly leveraged to the final outcome of this single clinical trial.

Anavex Life Sciences (AVXL)

• The speaker briefly discusses AVXL as a potential short.
• His thesis is simple and direct: "is AVXL a short? Well, the drug doesn't work. That's a good start."
• He mentions he prefers shorting stock directly rather than trading puts.

Takeaways

• This is a bearish call on AVXL, presenting it as a potential short-selling opportunity.
• The entire bear case presented here rests on the assertion that the company's lead drug is ineffective. Investors should conduct their own due diligence on the clinical data.

Investment Theme: Quantum Computing

• The speaker is overwhelmingly bearish on the publicly traded quantum computing sector.
• He states, "quantum's gotten so silly that even the quantum believers don't believe it" and "quantum's falling apart. I love it."
• Specific companies are viewed with deep skepticism:
  • IonQ (IONQ): He believes it will "eventually fall apart" and that "there's no way to actually grow real business here."
  • D-Wave (QBTS): A very direct call: "D-Wave is going to die."
  • Arqit Quantum (ARQQ): Dismissed as "not serious people."
  • Quantum Computing Inc. (QUBT): Mentioned as a company worth $2 billion that "barely have anything... I don't even think they have anything at all."
• A major risk factor is competition from private companies. He heard a rumor that a "privately held quantum company may be announcing something significant, which would not be good for these publicly traded ones." He specifically names Quantinium as a private company that is "going to suck a lot of money out of this space."

Takeaways

• Extreme caution is advised for investors in publicly traded quantum computing stocks like IONQ, QBTS, and ARQQ.
• The sector is viewed as a speculative bubble with companies that may lack viable technology or business models.
• The emergence of well-funded and potentially more advanced private competitors like Quantinium poses a significant threat to the existing public players.

Investment Theme: Cell Therapy

• The speaker is highly critical of a specific approach to cell therapy, which he believes is destined to fail.
• His thesis is that companies that simply "try to chuck cells into patients and pray that they engraft" are based on flawed science. He believes cell therapy is only viable when you "actually change something in the cell" (i.e., gene editing).
• He names several companies as examples of this flawed approach:
  • ProKidney (PROK) (see above)
  • Capricor Therapeutics (CAPR): He mentions data showing "99% of the cells are gone... within maybe even minutes" after infusion.
  • Mesoblast (MSB) is mentioned as another historical example of this failed strategy.

Takeaways

• Investors in the cell therapy space should be highly critical of companies whose strategy involves infusing unmodified allogeneic (donor) cells.
• According to this analysis, this approach has a long history of failure. The speaker suggests focusing on companies that are genetically engineering cells for specific therapeutic purposes.
• This provides a framework for evaluating and potentially shorting companies like PROK and CAPR.

Investment Theme: Bitcoin Miners as AI Plays

• The speaker discusses the popular investment narrative of Bitcoin miners pivoting to service the AI industry.
• He looks at IREN as an example: "Are these guys just a miner? Are they miner trying to do AI? It looks like it. I mean, this is the hot trade right now, right?"
• He acknowledges the logic, stating, "Miners are data centers to some extent."
• His tone is neutral to slightly positive, questioning why one would bet against this trend ("I don't know why you'd want to pick on these guys").

Takeaways

• The trend of Bitcoin miners leveraging their infrastructure (power, data centers) for AI computing is a significant theme.
• This narrative could provide a continued tailwind for stocks in the sector, like IREN.
• Investors interested in AI infrastructure could look at miners as a derivative or alternative way to play the trend, though it comes with the added volatility of the crypto market.

Other Brief Mentions

• PZIA: Mentioned as a stock that "is supposed to be a really good short" but has "already collapsed quite a bit."
• ARM Holdings (ARM): Briefly mentioned as "interesting," but the speaker notes he is not a semiconductor investor and doesn't have a strong opinion.
• Indian Stocks: The speaker confirms he is adding Indian stocks to his platform, indicating a general interest in the investment potential of that market.